Identification the monoclonal antibodies recognizing the α-synuclein N-terminal domain and their application in immunotherapy

doi:10.3969/j.issn.1006-7795.2023.06.018

Abstract

Abstract: Objective To analyze the specificity of five monoclonal antibodies 1C16, 2B8, 2P21, 3O18 and 1J6 that recognize α-synuclein (α-syn) N-terminal domains, to provide antibody support for early diagnosis and immunotherapy of Parkinson's disease (PD). Methods We generated human α-syn(h-α-syn), mouse α-syn (m-α-syn), β-syn, N-terminus human α-syn (α-syn/N) and delete N-terminus human α-syn (α-syn/ΔN) protein using recombinant protein purification technology in vitro. The specific recognition domains of the five monoclonal antibodies were detected by dot blotting. Using Western blotting to detect the denatured α-syn from purified protein and mice brain. Results Antibody 1C16 recognized h-α-syn proteins in native form and h-α-syn protein in the mice brain in denatured form rather than m-α-syn and β-syn. Antibody 1J6 could recognize h-α-syn and α-syn/N protein in native form rather than full-length α-syn protein and h-α-syn protein in the mouse brain in denatured form. Conclusion The two selected antibodies are specific to human α-syn, which provide the basis for the detection of biomarkers by enzyme linked immunosorbent assay and can be used for immunotherapy in PD.

Key words: Parkinson's disease, α-synuclein, α-synuclein N terminal, protein purification, monoclonal antibody

CLC Number:

R394

Jia Huanzhen, Jiao Jie, Gao Ge, Yang Hui. Identification the monoclonal antibodies recognizing the α-synuclein N-terminal domain and their application in immunotherapy[J]. Journal of Capital Medical University, 2023, 44(6): 1022-1028.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.06.018

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I6/1022

References

［1］Lashuel H A, Overk C R, Oueslati A, et al. The many faces of α-synuclein: from structure and toxicity to therapeutic target［J］. Nat Rev Neurosci, 2013, 14(1): 38-48.
［2］Binolfi A, Limatola A, Verzini S, et al. Intracellular repair of oxidation-damaged α-synuclein fails to target C-terminal modification sites［J］. Nat Commun, 2016, 7(1): 10251.
［3］Kang L J, Janowska M K, Moriarty G M, et al. Mechanistic insight into the relationship between N-terminal acetylation of α-synuclein and fibril formation rates by NMR and fluorescence［J］. PLoS One, 2013, 8(9): e75018.
［4］Oueslati A, Fournier M, Lashuel H A. Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein: implications for Parkinson's disease pathogenesis and therapies［J］. Prog Brain Res, 2010, 183: 115-145.
［5］Gribaudo S, Tixador P, Bousset L, et al. Propagation of α-synuclein strains within human reconstructed neuronal network［J］. Stem Cell Reports, 2019, 12(2): 230-244.
［6］Liu W J, Zhang Q D, Xing H, et al. Characterization of a novel monoclonal antibody for serine-129 phosphorylated α-synuclein: a potential application for clinical and basic research［J］. Front Neurol, 2022, 13: 821792.
［7］Shen J M, Du T T, Wang X, et al. α-Synuclein amino terminus regulates mitochondrial membrane permeability［J］. Brain Res, 2014, 1591: 14-26.
［8］Foulds P G, Mitchell J D, Parker A, et al. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease［J］. FASEB J, 2011, 25(12): 4127-4137.
［9］Inglis K J, Chereau D, Brigham E F, et al. Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system［J］. J Biol Chem, 2009, 284(5): 2598-2602.
［10］Delenclos M, Burgess J D, Lamprokostopoulou A, et al. Cellular models of α-synuclein toxicity and aggregation［J］. J Neurochem, 2019, 150(5): 566-576.
［11］Zhang Z T, Kang S S, Liu X, et al. Asparagine endopeptidase cleaves α-synuclein and mediates pathologic activities in Parkinson's disease［J］. Nat Struct Mol Biol, 2017, 24(8): 632-642.
［12］Games D, Valera E, Spencer B, et al. Reducing C-terminal-truncated α-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models［J］. J Neurosci, 2014, 34(28): 9441-9454.
［13］Wang Z P, Gao G, Duan C L, et al. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease［J］. Biomed Pharmacother, 2019, 115: 108843.
［14］Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial［J］. JAMA Neurol, 2018, 75(10): 1206-1214.
［15］Lynch S M, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of α-synuclein reduces intracellular aggregation and toxicity［J］. J Mol Biol, 2008, 377(1): 136-147.

[1]	Wang Jing, Zhang Guoyan, Cheng Shan. ood practices in Mendelian randomization： common designs, key challenges, and optimization in Mendelian randomization analysis [J]. Journal of Capital Medical University, 2023, 44(6): 1087-1094.
[2]	Liu Yongmei, Zheng Shuangli, Chen Danying, Song Yanjun, Li Xinglin, Qiu Yaruo, Song Chuan, Zhang Yuanyuan, Wang Xi, Zhao Xuesen. LY6E inhibit the entry of different variants of SARS-CoV-2 mediated by the spike protein [J]. Journal of Capital Medical University, 2023, 44(4): 652-662.
[3]	Zhang Jianxiong, Li Dandan, Hu Mengmeng, Cheng Xuewei, Dong Ruihua. Relationship between carboxylesterase 1 and carboxylesterase 2 gene expression levels and body mass index, and gene polymorphism analysis [J]. Journal of Capital Medical University, 2023, 44(1): 13-19.
[4]	Dong Lingyue, Wang Yutong. Tracing the evolutionary history of humans——Introduction of the Nobel Prize in Physiology or Medicine 2022 [J]. Journal of Capital Medical University, 2022, 43(5): 804-806.
[5]	Li Wei, Hao Chanjuan. Exploring the etiology of pediatric inherited disorders——Dr. Li Wei's Laboratory [J]. Journal of Capital Medical University, 2020, 41(5): 730-735.
[6]	Luo Jianan, Yang Shufa, Yu Xiuyi, Liu Xin, Chen Zhenwen. Establishment a mesenchymal stem cell line model derived from Klinefelter syndrome fetal umbilical cord [J]. Journal of Capital Medical University, 2019, 40(6): 868-874.
[7]	HUA Bing;YANG Meng-han;CHI Ya-fei;WANG Chao. HEY gene family in mammalian cardiovascular development [J]. Journal of Capital Medical University, 2012, 33(4): 534-537.
[8]	Zhu Wanwan;Wang Shuyan;Wu Di;Xu Yanling;Fu Linlin;Guan Yunqian;Zhang Yu. Comparison between Trypsinization and Collagenase Treatment in Passaging of Human Embryonic Stem Cells [J]. Journal of Capital Medical University, 2008, 29(4): 445-450.
[9]	Liang Kuo;Li Fei . Advances of Study on PSP/reg Geng [J]. Journal of Capital Medical University, 2007, 28(6): 794-797.
[10]	Cai Yanning;Zuo Xiaohong;Liu Shu;Xie Shu;Wen Mei;Chen Biao. Expression Profiling of Per1 Gene in Mouse Striatum Detected Using Real Time RT-PCR [J]. Journal of Capital Medical University, 2006, 27(1): 63-65.
[11]	Wang Zhe;Zhang Jinfeng;Fu Guifang . Effect of Rhizoma Curcumate Zedoariae and Herbra Trifolii Repentis on Apoptosis of Human Lung Cancer Cell Line A549 [J]. Journal of Capital Medical University, 2001, 22(4): 304-305.
[12]	. [J]. Journal of Capital Medical University, 1997, 18(3): 234-234.